Ocular Therapeutix share price logo

Ocular Therapeutix

NASDAQ: OCUL

Mid Cap

$11.09

-0.64

(-5.50%)

as on

Ocular Therapeutix Stock Performance

as on August 21, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $11.07
    $11.62
    downward going graph

    0.18%

    Downside

    4.78%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $6.23
    $16.44
    downward going graph

    43.82%

    Downside

    48.24%

    Upside

    downward going graph

Ocular Therapeutix share price movements today

Previous Close
$11.73
Open
$11.53
Volume
2.5M
Market Cap
$2.2B
Day's Low - High
$11.07 - $11.62
52 Week Low - High
$6.23 - $16.44

Ocular Therapeutix Historical Returns

1 Month Return
+ 11.93 %
3 Month Return
+ 9.61 %
1 Year Return
-20.44 %
3 Year Return
+ 132.95 %
5 Year Return
-1.47 %

Ocular Therapeutix Stock Fundamentals & Key Indicators

Check Ocular Therapeutix market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.2B

EPS (TTM)

-1.42

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-7.11

Industry PE ratio

-13.046547619047619

PEG Ratio

0.6265950195200128

EBITDA

-284.6M

Revenue (TTM)

52.1M

Profit Margin

87.11%

Return On Equity TTM

-59.87%

Ocular Therapeutix Stock Valuation

Track how Ocular Therapeutix P/E has moved over time to understand its valuation trends.

Ocular Therapeutix in the last 5 years

  • Overview

  • Trends

Lowest (-81.25x)

December 31, 2021

Industry (-13.05x)

December 31, 2025

Today (-8.55x)

December 31, 2025

Highest (-3.04x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -8.55x

Ocular Therapeutix vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Ocular Therapeutix with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$2.2B-1.47%-7.1187.11%NA
BUY$43.7B669.3%NA0.00%NA
BUY$128.2B154.86%29.8286.04%NA
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Ocular Therapeutix Stock including INR - Dollar returns

The Ocular Therapeutix stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Ocular Therapeutix investment value today

Current value as on today

₹96,639

Returns

-₹3,361

(-3.36%)

Returns from Ocular Therapeutix Stock

-₹12,124 (-12.12%)

Dollar Impact

₹8,763 (+8.76%)

Analyst Recommendation on Ocular Therapeutix Stock

Based on 10 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 10 analysts, 100% of analysts recommend a 'BUY' rating for Ocular Therapeutix. Average target price of $27.09

Ocular Therapeutix Share Price Target

Get share price movements and forecasts by analysts on Ocular Therapeutix.

What analysts predicted

59.06%UPSIDE

Target Price

$27.09

Current Price

$11.09

Analyzed by

10 Analysts

Target

$27.09

Ocular Therapeutix target price $27.09, a slight upside of 59.06% compared to current price of $11.09. According to 10 analysts rating.

Indian Investors' Interest in Ocular Therapeutix Stock

Search interest for Ocular Therapeutix Stock has decreased by -43% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-43% versus previous 30 day period

Ocular Therapeutix Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
14
16
15
17
10
13
14
13
10
13
Gross Profit
13
14
13
15
9
11
12
11
9
11
Operating Income
-31
-43
-45
-50
-63
-67
-68
-69
-93
-82
EBITDA
-59
-39
-32
-44
-60
-63
-65
-60
-84
-74
Interest Expense
4
3
3
3
2
3
3
2
2
2
Depreciation
0
0
0
0
0
1
1
1
1
1
Income Before Tax
-64
-43
-36
-48
-64
-67
-69
-64
-88
-78
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-64
-43
-36
-48
-64
-67
-69
-64
-88
-78
Net Profit Margin
91.02%
90.82%
89.88%
92.80%
88.20%
85.56%
87.80%
87.97%
87.68%
85.08%

Ocular Therapeutix Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
1
4
17
43
51
58
63
51
Gross Profit
1
1
1
15
39
46
53
58
45
Operating Income
-61
-59
-85
-62
-78
-78
-82
-171
-270
EBITDA
-59
-55
-77
-146
2
-61
-66
-176
-249
Interest Expense
1
1
6
6
6
7
11
13
11
Depreciation
1
2
2
2
2
2
2
3
4
Income Before Tax
-63
-59
-86
-155
-6
-71
-80
-193
-265
Income Tax Expense
0
-2
-
-
-
-
-
-
-
Net Income
-63
-57
-86
-155
-6
-71
-80
-193
-265
Net Profit Margin
76.24%
76.63%
45.00%
88.03%
89.88%
91.18%
90.96%
91.17%
87.31%

Ocular Therapeutix Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-64
-43
-36
-48
-64
-67
-69
-64
-88
-78
Operating Cash Flow
-33
-24
-36
-39
-44
-55
-50
-54
-65
-67
Investing Cash Flow
0
0
0
0
-1
-1
-5
-2
-4
-3
Financing Cash Flow
321
2
4
4
4
97
10
449
0
2
Change in Cash
287
-23
-32
-35
-42
41
-46
392
-70
-68

Ocular Therapeutix Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-63
-59
-86
-155
-6
-71
-80
-193
-265
Operating Cash Flow
-50
-49
-77
-53
-65
-59
-70
-134
-204
Investing Cash Flow
27
-1
-2
0
-1
-3
-6
-1
-11
Financing Cash Flow
32
68
75
228
2
1
169
332
561
Change in Cash
8
17
-4
173
-63
-61
93
196
344

Mutual Funds that own Ocular Therapeutix Stock

Check out the Mutual Funds with significant holdings in Ocular Therapeutix.

Funds
Holdings
Shares Held
Fidelity Mt. Vernon Street Trust
6.636261%
14574284
VANGUARD INDEX FUNDS
3.870215%
8499607
Fidelity Select Portfolios
1.188553%
2610252
Fidelity Salem Street Trust
0.924061%
2029385
Northern Funds
0.061398%
134840

Global Institutional Holdings in Ocular Therapeutix

Funds
Holdings
Vanguard
4.78%
iShares
3.91%
SPDR
0.78%
Invesco
0.76%
Michael Rockefeller
0.76%

Ocular Therapeutix News & Key Events

  • img

    Today's Timeline - 17 June

    Wed, 09:39 PM

    -

    Ocular Therapeutix shares climbed 5% after outlining regulatory path for Axpaxli therapy ahead of Investor Day presentation.

Insights on Ocular Therapeutix

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 10.78M → 13.47M (in $), with an average increase of 20.0% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -88.61M → -78.76M (in $), with an average increase of 12.5% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, OCUL stock has moved up by 16.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 624.7% return, outperforming this stock by 445.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 493.6% return, outperforming this stock by 495.5%

About Ocular Therapeutix

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
OrganisationOcular Therapeutix
Headquarters14 Crosby Drive, Bedford, MA, United States, 01730
IndustryBiotechnology
CEODr. Pravin U. Dugel M.D.
E-voting on sharesClick here to vote

Key Management of Ocular Therapeutix

Name

Title

Mr. Sanjay Nayak MBBS, Ph.D.

Chief Strategy Officer

Dr. Peter K. Jarrett Ph.D.

Chief Technical Officer

Dr. Jeffrey S. Heier M.D.

Chief Scientific Officer

Mr. William S. Slattery Jr.

Vice President of Investor Relations

Dr. Pravin U. Dugel M.D.

Executive Chairman, President & CEO

Mr. Donald Notman Jr.

Chief Operating Officer (Leave of Absence)

Mr. Steve Meyers

Chief Commercial Officer

Dr. Nadia K. Waheed M.D., M.P.H.

Chief Medical Officer

Mr. Jason Robins

CFO & Principal Accounting Officer

Mr. Todd D.C. Anderman J.D.

Chief Legal Officer & Corporate Secretary

FAQs

What is Ocular Therapeutix share price today?

Ocular Therapeutix share price today is $11.09 as on at the close of the market. Ocular Therapeutix share today touched a day high of $11.62 and a low of $11.07.

What is the 52 week high and 52 week low for Ocular Therapeutix share?

Ocular Therapeutix share touched a 52 week high of $16.44 on and a 52 week low of $6.23 on . Ocular Therapeutix stock price today i.e. is closed at $11.09,which is 32.54% down from its 52 week high and 78.01% up from its 52 week low.

What is Ocular Therapeutix's market capitalisation today?

Ocular Therapeutix market capitalisation is $0.00T as on .

How to invest in Ocular Therapeutix Stock (OCUL) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Ocular Therapeutix on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ocular Therapeutix Shares that will get you 0.1353 shares as per Ocular Therapeutix share price of $11.09 per share as on August 21, 2026 at 1:29 am IST.

What is the minimum amount required to buy Ocular Therapeutix Stock (OCUL) from India?

Indian investors can start investing in Ocular Therapeutix (OCUL) shares with as little as ₹95.695 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.95 in Ocular Therapeutix stock (as per the Rupee-Dollar exchange rate as on ). Based on Ocular Therapeutix share’s latest price of $11.09 as on August 21, 2026 at 1:29 am IST, you will get 0.9017 shares of Ocular Therapeutix. Learn more about fractional shares .

What are the returns that Ocular Therapeutix has given to Indian investors in the last 5 years?

Ocular Therapeutix stock has given -1.47% share price returns and 28.59% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?